## Schedule

**Wednesday, Nov. 1, 2023 | 2–5:45 p.m. PDT**

### Session I: Review of Early-stage Disease, What We’ve Learned, Recent Approvals in the Perioperative Setting

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>2–3:10 p.m. PDT</td>
<td>Introduction</td>
</tr>
<tr>
<td>2:05 p.m. PDT</td>
<td>Immunotherapy in Resectable Lung Cancer: Pre-op, Post-op, Both, or Neither?</td>
</tr>
<tr>
<td>2:25 p.m. PDT</td>
<td>Expanding Adjuvant Therapy to Earlier Stage Melanoma: The Risk is in the Biology of the Primary Lesion - Not the Nodes!</td>
</tr>
<tr>
<td>2:45 p.m. PDT</td>
<td>Panel Discussion, Question and Answer</td>
</tr>
</tbody>
</table>

**Moderator:** Jane Anne Healy, MD, PhD – Merck Sharp & Dhome LLC

**Panelists:**
- Mark Awad, MD, PhD – Dana-Farber Cancer Institute
- Jason J. Luke, MD, FACP – UPMC Hillman Cancer Center

### Session II: Predictive Biomarkers and Surrogate Endpoints

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:10 p.m. PDT</td>
<td>Introduction</td>
</tr>
<tr>
<td>3:15 p.m. PDT</td>
<td>Predictive Biomarkers and Surrogate Endpoints: The Role of ctDNA</td>
</tr>
<tr>
<td>3:35 p.m. PDT</td>
<td>Pathologic Complete Response</td>
</tr>
</tbody>
</table>

**Moderator:** Giovanni Melillo, MD – AstraZeneca

**Panelists:**
- Christian Rolfo, MD, PhD, MBA – Icahn School of Medicine at Mount Sinai
- Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Schedule

3:55 p.m. PDT  Panel Discussion, Question and Answer
Moderator:  Giovanni Melillo, MD – AstraZeneca
Panelists:  Julie R. Brahmer, MD – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Christian Rollo, MD, PhD, MBA – Icahn School of Medicine at Mount Sinai

Session III: Trial Design, Endpoint Validation, Statistical and Regulatory Considerations

Time:  4:30–5:45 p.m. PDT
Location:  Upper Level – Ballroom 6CD
San Diego Convention Center
Moderator:  Nicholas Botwood, MD – Bristol Myers Squibb

4:30 p.m. PDT  Introduction
Nicholas Botwood, MD – Bristol Myers Squibb

4:35 p.m. PDT  Exploring the use of ctDNA for Monitoring Treatment Response
Jeff Allen, PhD – Friends of Cancer Research

4:55 p.m. PDT  FDA Contribution of Components
Marc Theoret, MD – Food and Drug Administration (FDA)

5:15 p.m. PDT  Panel Discussion, Question and Answer
Moderator:  Nicholas Botwood, MD – Bristol Myers Squibb
Panelists:  Jeff Allen, PhD – Friends of Cancer Research
Marc Theoret, MD – Food and Drug Administration (FDA)

5:40 p.m. PDT  Concluding Remarks
Nicholas Botwood, MD – Bristol Myers Squibb

Industry Program Reception

Time:  5:45–6:45 p.m. PDT
Location:  Upper Level – West Terrace
San Diego Convention Center